Dengue Literature Review

Autoantigen Microarray

3 min read

Autoantigen Microarray

Overview

Autoantigen microarray (also called autoantibody microarray or antigen protein array) is a high-throughput method for simultaneously profiling autoantibody reactivity against hundreds of self-antigens from a single plasma or serum sample. Purified self-antigens are spotted in duplicate onto a nitrocellulose-coated slide; patient plasma is incubated with the array; bound IgG and IgM autoantibodies are detected with fluorescently labelled anti-human secondary antibodies and quantified using a laser scanner. The result is a normalized fluorescence intensity (NFI) value for each antigen–isotype combination, allowing direct comparison across patients and groups.

Key Points from Literature

Platform and workflow

  • The platform used in dengue research (see Vo2020 - Autoantibody Profiling in Dengue) is the autoantigen microarray developed at the University of Texas Southwestern Medical Center (Zhu et al. 2015, originally validated in SLE), carrying 123 self-antigens covering nuclear proteins, basement membrane proteins, coagulation factors, complement components, and cell stress-related proteins, plus 4 control proteins — 127 spots total, printed in duplicate
  • Plasma is pre-treated with DNase-I to remove free circulating DNA (which can bind nuclear antigen spots non-specifically) and diluted 1:50 in PBST buffer before incubation
  • Detection: cy3-conjugated anti-human IgG (1:2000) and cy5-conjugated anti-human IgM (1:2000) simultaneously, using a Genepix 4200A scanner at 532 and 635 nm; images analysed in Genepix Pro 7.0
  • NFI calculation: median spot signal minus local background, averaged across duplicates, normalised to the mean intensity of IgG/IgM internal controls spotted on the array, then PBS-blank-subtracted
  • Signal-to-noise ratio (SNR) ≥ 3 is the positivity threshold

Analytic strengths

  • Simultaneous profiling of IgM and IgG across the full antigen panel without prior knowledge of target specificity — an unbiased screen
  • Enables identification of novel autoantibody targets not captured by targeted single-analyte assays (ELISA, IIFA, LIA)
  • Can detect subtle quantitative differences across patient groups even when the absolute signal is below the SNR positivity threshold (using continuous NFI values and group-level statistics)

Analytic limitations

  • Low throughput per experiment: slide-based format; each sample consumes a full slide; not suitable for very large cohorts without significant resources
  • Cross-validation not feasible with limited sample volume: small plasma volumes preclude repeat or orthogonal validation
  • No confirmatory isotype specificity: reports total IgG or IgM signal; cannot distinguish specific IgG subclasses (IgG1–IgG4) or free vs. immune-complex-bound antibodies
  • Multiple comparisons burden: 123 antigens × 2 isotypes = 246 possible comparisons; Bonferroni correction would require p < 0.0002 for each individual test — thresholds rarely applied in exploratory studies, limiting interpretation of individual positive findings

Application in dengue

In Vo2020 - Autoantibody Profiling in Dengue, the platform was used to characterise the autoantibody repertoire in Cambodian pediatric dengue patients (ASD, DF, DHF) vs. healthy donors. Key findings enabled by the breadth of the array:

  • Identification of 80 IgM and 6 IgG autoantibodies elevated across DENV-infected vs. HD
  • Discovery of the primary > secondary IgG autoantibody finding — a relationship not testable by single-target assays
  • Identification of 19 IgG autoantibodies correlating with platelet counts in DHF, spanning complement, coagulation, and nuclear antigens — a cross-domain pattern only visible with an untargeted screen

Contradictions & Debates

  • NFI-based array results require independent validation by orthogonal methods (ELISA, IIFA, flow cytometry) before clinical utility can be claimed; array findings are hypothesis-generating
  • Bystander polyclonal activation during infection inflates the number of “positive” signals; interpretation of individual elevated antibodies as specifically relevant to pathogenesis requires absorption or functional follow-up experiments

Sources

Graph View

Backlinks